Securities code: 300558 securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022-007 Betta Pharmaceuticals Co.Ltd(300558)
Announcement of resolutions of the 22nd Meeting of the third board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
1. The meeting of the board of supervisors was convened by Mr. Zhang Yangnan, chairman of the board of supervisors. The meeting notice was sent to all supervisors by e-mail and telephone on January 14, 2022. The meeting notice of the board of supervisors includes relevant materials of the meeting and lists the time, place, content and method of the meeting.
2. On January 21, 2022, the board of supervisors held an on-site meeting in the conference room on the third floor of the company’s Hangzhou headquarters and voted on the spot.
3. The board of supervisors should have 3 people, and the actual number of people attending the meeting is 3.
4. The board of supervisors is presided over by Mr. Zhang Yangnan, chairman of the board of supervisors.
5. The convening, convening and voting procedures of this meeting comply with the company law of the people’s Republic of China and other laws and regulations and the relevant provisions of the Betta Pharmaceuticals Co.Ltd(300558) articles of association.
2、 Deliberation at the meeting of the board of supervisors
The meeting considered and adopted the following proposals:
1. The proposal on investment in Zhejiang shimai Pharmaceutical Co., Ltd. and related party transactions was deliberated and adopted
In order to accelerate the layout of Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) in the field of antibody drugs and expand the in-depth exchange of innovative drug technologies, The company plans to invest RMB 30 million through its wholly-owned subsidiary BeDa biomedical technology (Zhejiang) Co., Ltd. (hereinafter referred to as “BeDa biology”) and subscribe for the newly increased registered capital of Zhejiang shimai Pharmaceutical Co., Ltd. (hereinafter referred to as “shimai pharmaceutical”) of RMB 248199, with a post investment contribution ratio of 1.3453%. The board of supervisors of the company agrees to this matter. For details, see the company’s disclosure on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on investment in Zhejiang shimai Pharmaceutical Co., Ltd. and related party transactions (Announcement No.: 2022-008).
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
2. The proposal on the transfer of part of the equity and related party transactions of Zhejiang shimai Pharmaceutical Co., Ltd. was deliberated and passed. In order to accelerate the company’s layout in the field of antibody drugs, BeDa biology plans to invest 76 million yuan to transfer the 628772 yuan capital contribution of shimai pharmaceutical held by Kaiming investment, i.e. 3.4081% equity. The board of supervisors of the company agrees to this matter. For details, see the company’s disclosure on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on the transfer of part of the equity and related party transactions of Zhejiang shimai Pharmaceutical Co., Ltd. (Announcement No.: 2022-009).
Voting results: 3 in favor, 0 against and 0 abstention. The proposal was passed.
3、 Documents for future reference
1. Betta Pharmaceuticals Co.Ltd(300558) resolution of the 22nd Meeting of the third board of supervisors.
It is hereby announced.
Betta Pharmaceuticals Co.Ltd(300558) board of supervisors January 23, 2022
